Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS­CoV­2 Infection: A Review of Current Evidence".

Lenze, Eric J; Reiersen, Angela M; Facente, Shelley N

Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".

Lenze, Eric J; Reiersen, Angela M; Facente, Shelley N.

Lenze EJ; Washington University in St. Louis, St. Louis, Missouri, USA.
Reiersen AM; Washington University in St. Louis, St. Louis, Missouri, USA.
Facente SN; University of California, Berkeley, 2121 Berkeley Way West, 5th Floor, Berkeley, CA, 94720, USA. sfacente@berkeley.edu.

Drugs ; 82(3): 353-354, 2022 02.

Article in English | MEDLINE | ID: covidwho-1679473

Subject(s)

COVID-19 Drug Treatment; Fluvoxamine; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Drugs Year: 2022 Document Type: Article Affiliation country: S40265-022-01681-8

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google